Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xinqing Lin
Observed names:
X. Lin,
Xin-Qing Lin,
Xin-qing Lin
Institutions:
First Affiliated Hospital of Guangzhou Medical University,
Guangzhou Institute of Respiratory Health
Observed institutions:
Qingdao University,
First Affiliated Hospital of Guangzhou Medical University,
Affiliated Hospital of Qingdao University,
State Key Laboratory of Respiratory Disease,
Guangzhou Institute of Respiratory Health,
Guangzhou Medical University
show all 6
ORCID:
0000-0002-1582-7700
Observed ORCID:
0000-0002-1582-7700
OpenAlex ID:
A5102799595
Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma
2020
·
Xinqing Lin
, Liqiang Wang
, et al.
·
Frontiers in Molecular Biosciences
·
52
PDF
Induction chemotherapy followed by camrelizumab plus apatinib and chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, single-arm trial
2025
·
Ming Liu
, Guihuan Qiu
, et al.
·
Signal Transduction and Targeted Therapy
·
26
PDF
International guidelines on the diagnosis and treatment of NUT carcinoma
2025
·
Yu Zhang
, Qi Zhang
, et al.
·
The Innovation
·
20
Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer
2022
·
Xiaohong Xie
, Jianhui Wu
, et al.
·
Respiratory Research
·
15
PDF
Antithrombin-III without concomitant heparin improves endotoxin-induced acute lung injury rats by inhibiting the activation of mitogen-activated protein kinase.
2009
·
Hui-ming Sun
, Ling-zhi Hong
, et al.
·
PubMed
·
13
A case report and literature review on respiratory failure with immune checkpoint inhibitors: a life-threatening adverse event
2023
·
Xinqing Lin
, Wenhui Guan
, et al.
·
Immunopharmacology and Immunotoxicology
·
8
Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer
2023
·
Zhixuan You
, Haotian Zhang
, et al.
·
Cancers
·
7
PDF
Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events
2025
·
Tao Luan
, Jianqing Hao
, et al.
·
Human Vaccines & Immunotherapeutics
·
3
PDF
First-in-human study of dosimetry, safety and efficacy for [177Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases
2024
·
Ruiyue Zhao
, Jie Lv
, et al.
·
European Journal of Nuclear Medicine and Molecular Imaging
·
3
A comprehensive analysis of LINC00958 as a prognostic biomarker for head and neck squamous cell carcinoma
2023
·
R. Li
, P. An
, et al.
·
International Journal of Oral and Maxillofacial Surgery
·
3
Integrative GWAS and Mendelian Randomization Analysis Identifies IREB2 and CD27+ Memory B Cells as Core Drivers of COPD to Lung Cancer Progression
2025
·
Erkang Yi
, Qingyang Li
, et al.
·
MedComm
·
1
PDF
Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer
2026
·
Ying-Bo Xie
, Yi-Ke Wang
, et al.
·
Translational Lung Cancer Research
Phase I Clinical Trial of Autologous Hematopoietic Stem Cell Transplantation-Supported Dose-Intensified Chemotherapy With Adebrelimab as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
2024
·
Ming Liu
, Wenhui Guan
, et al.
·
Clinical Lung Cancer
Sintilimab Combined with Gemcitabine and Carboplatin for First-Line Treatment of Locally Advanced or Metastatic Pulmonary Lymphoepithelioma-Like Carcinoma: A Multicenter, Single-Arm, Phase II Trial
2024
·
Chengzhi Zhou
, Xin-Qing Lin
, et al.
·
SSRN Electronic Journal
Sputum supernatant as a viable alternative for liquid biopsy in advanced non-small cell lung cancer.
2021
·
Cheng-Zhi Zhou
, Xiaohong Xie
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
15
Citation count:
151
H-index:
7
I10-index:
5
Year
Topic
Type